Uremic cardiomyopathy: An underdiagnosed disease

Congestive Heart Failure

Volumn 19, Issue 4, 2013, Pages

  Alhaj, Eyad ^a   Alhaj, Nehad ^a   Rahman, Ifad ^a   Niazi, Tariq O ^a   Berkowitz, Robert ^a   Klapholz, Marc ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; ENDOTHELIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; LEPTIN; PARATHYROID HORMONE; RAMIPRIL; RAPAMYCIN; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; AORTA STENOSIS; ARTERIOSCLEROSIS; ARTERIOVENOUS FISTULA; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIASTOLIC DYSFUNCTION; DISEASE COURSE; ECHOCARDIOGRAPHY; EPIDEMIOLOGICAL MONITORING; EXPERIMENTAL THERAPY; EXTRACELLULAR MATRIX; GLOMERULUS FILTRATION RATE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOME DIALYSIS; HUMAN; HYPERPARATHYROIDISM; HYPERTENSION; HYPERVOLEMIA; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALNUTRITION; MOLECULAR PATHOLOGY; MOLECULAR WEIGHT; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW; STUNNED HEART MUSCLE; SURVIVAL; SYSTOLIC DYSFUNCTION; ULTRAFILTRATION; UREMIA; UREMIC CARDIOMYOPATHY;

CARDIOMYOPATHIES; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; HUMANS; MORBIDITY; UREMIA; WORLD HEALTH;

EID: 84881312058     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/chf.12030     Document Type: Review

References (70)

1. Cheung AK, Sarnak MJ, Yan G, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 2000;58:353-362.
2. Sarnak MJ, Coronado BE, Greene T, et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol. 2002;57:327-335.
3. Longenecker JC, Coresh J, Powe NR, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol. 2002;13:1918-1927.
4. Chonchol M, Whittle J, Desbien A, et al. Chronic kidney disease is associated with angiographic coronary artery disease. Am J Nephrol. 2008;28:354-360.
5. Stack AG, Bloembergen WE. Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. J Am Soc Nephrol. 2001;12:1516-1523.
6. Rostand SG, Kirk KA, Rutsky EA. Dialysis associated ischemic heart disease: insights from coronary angiography. Kidney Int. 1984;25:653-659.
7. Rostand SG, Gretes JC, Kirk KA, et al. Ischemic heart disease in patients with uremia undergoing maintenance hemodialysis. Kidney Int. 1979;16:600-611.
8. Clyne N, Lins LE, Pehrsson SK. Occurrence and significance of heart disease in uraemia: an autopsy study. Scand J Urol Nephrol. 1986;20:307-311.
9. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395-1407.
10. Jardine AG, McLaughlin K. Cardiovascular complications of renal disease. Heart. 2001;86:459-466.
11. Siedlecki A, Muslin AJ. Left ventricular hypertrophy in the setting of chronic kidney disease-mechanisms and treatment. US Nephrol. 2008;3:40-42.
12. Mark PB, Johnston N, Groenning BA, et al. Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int. 2006;69:1839-1845.
13. Nolan CR. Strategies for improving long-term survival in patients with ESRD. J Am Soc Nephrol. 2005;16:S120-S127.
14. U.S. Renal Data System, USRDS 2099 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2009. The data reported here have been supplied by the United Stated Renal Data System (USRDS).
15. Wolf WC, Agata J, Chao L, Chao J. Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. Kidney Int. 2000;58:730-739.
16. McMahon AC, Dodd SM, Hurst MJ, Raine AE. Prolonged calcium transients and myocardial remodelling in early experimental uremia. Nephrol Dial Transplant. 2000;17:759-764.
17. Raev DC. Which left ventricular function is impaired earlier in the evolution of diabetic cardiomyopathy? An echocardiographic study of young type I diabetic patients. Diabetes Care. 1994;17:633-639.
18. Nielsen FS, Ali S, Tarnow L, et al. Beneficial impact of ramipril on left ventricular hypertrophy in normotensive non-albuminuric NIDDM patients. Diabetes Care. 1998;21:804-809.
19. Yutao X, Xiaojun B, Tao G, Aiqun M. Mechanical stretch-induced hypertrophy of neonatal rat ventricular myocytes is mediated by beta (1)-integrin-microtubule signaling pathways. Eur J Heart Fail. 2006;8:16-22.
20. Yamazaki T, Kudoh S, Zou Y, et al. Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy. Circ Res. 1995;77:258-265.
21. Yamazaki T, Kudoh S, Zou Y, et al. Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J Biol Chem. 1996;271:3221-3228.
22. Winchester JF. Extracorporeal strategies for the removal of middle molecules. Semin Dial. 2006;19:110-114.
23. Lingrel JB, O'Brien W, Jewell-Motz E, Askew R. Related structure function studies of the NKA. Kidney Int Suppl. 1994;44:S32-S39.
24. Fedorova O, Talan MI, Agalakova N, et al. Co-ordinated shifts in NKA isoforms and their endogenous ligands during cardiac hypertrophy and failure in NaCl-sensitive hypertension. J Hypertension. 2004;22:389-397.
25. Kennedy DJ, Malhotra D, Shapiro JI. Molecular insights into uremic cardiomyopathy: cardiotonic steroids and Na/K ATPase signaling. Cell Mol Biol (Noisy-le-grand) 2006;52:3-14.
26. Shinohara K, Shoji T, Emoto M, et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol. 2002;13:1894-1900.
27. Becker B, Kronenberg F, Kielstein JT, et al; MMKD Study Group: renal insulin resistance syndrome, adiponectin, and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol. 2005;16:1091-1098.
28. Semple D, Smith K, Bhandari S, Seymour AML. Uremic cardiomyopathy and insulin resistance: a critical role for akt. J Am Soc Nephrol. 2011;22:207-215.
29. Dogra G, Irish A, Chan D, Watts G. Insulin resistance, inflammation, and blood pressure determine vascular dysfunction in CKD. Am J Kidney Dis. 2006;48:926-934.
30. Nishimura M, Murase M, Hashimoto T, et al. Insulin resistance and impaired myocardial fatty acid metabolism in dialysis patients with normal coronary arteries. Kidney Int. 2006;69:553-559.
31. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int. 1989;36:286-290.
32. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis. 1999;34:125-134.
33. London GM, Pannier B, Guerin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol. 2001;12:2759-2767.
34. Zoccali C, Benedetto FA, Tripepi G, et al; Creed Investigators: cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol. 2001;12:1508-1515.
35. Adhyapak SM, Iyengar SS. Characteristics of a subset of patients with reversible systolic dysfunction in chronic kidney disease. Congest Heart Fail. 2011;17:120-126.
36. Yu WC, Lin IF, Chuang SY, Chen CH. Effect of ramipril on left ventricular mass in normotensive hemodialysis patients. Am J Kidney Dis. 2006;47:478-484.
37. Cowan BR, Young AA. Left ventricular hypertrophy and renin-angiotensin system blockade. Curr Hypertens Rep. 2009;11:167-172.
38. Burns J, Ball SG, Worthy G, et al. Hypertensive left ventricular hypertrophy: a mechanistic approach to optimizing regression assessed by cardiovascular magnetic resonance. J Hypertens. 2012;30:2039-2046.
39. Hwang SC, Yang WC, Lin M, et al. Impact of the clinical conditions at dialysis initiation on mortality in incidence hemodialysis: a national cohort study in Taiwan. Nephrol Dial Transplant. 2010;25:2616-2624.
40. Stel VS, Dekker FW, Ansell D, et al. Residual renal function at the start of dialysis and clinical outcomes. Nephrol Dial Transplant. 2009;24:3175-3182.
41. Traynor JP, Simpson K, Geddes CC, et al. Early initiation of dialysis fails to prolong survival in patients with end-stage renal failure. J Am Soc Nephrol. 2002;13:2125-2132.
42. Korevaar JC, Jansen MA, Dekker FW, et al. When to initiate dialysis: effect of proposed US guidelines on survival. Lancet. 2001;358:1046-1050.
43. Sawhney S, Djurdjev O, Simpson K, et al. Survival and dialysis initiation: comparing British Columbia and Scotland registries. Nephrol Dial Transplant. 2009;24:3186-3192.
44. Academic Medical Center, Department of Medical Informatics, Amsterdam, The Netherlands. ERA/EDTA Registry Annual Report 2007. http://www.era-edta-reg.org/files/annualreports. Accessed June 2009.
45. Van Biesen W, Vanholder R. When to start chronic dialysis: tunnel vision induced by numbers? Nephrol Dial Transplant 2010;25:2405-2407.
46. European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association. Section I. Measurement of renal function, when to refer and when to start dialysis. Nephrol Dial Transplant 2002;17:7-15.
47. Parfrey PS, Foley RN, Harnett JD, et al. Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplant. 1996;11:1277-1285.
48. Breidthardt T, McIntyre CW. Dialysis-induced myocardial stunning: the other side of the cardiorenal syndrome. Rev Cardiovasc Med. 2011;12:13-20.
49. Selby NM, McIntyre CW. The acute cardiac effects of dialysis. Semin Dial. 2007;20:220-228.
50. Dorairajan S, Chockalingam A, Misra M. Myocardial stunning in hemodialysis: what is the overall message? Hemodial Int. 2010;14:447-450.
51. Enia G, Mallamaci F. Long-term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than haemodialysis patients. Nephrol Dial Transplant. 2001;16:1459-1464.
52. McIntyre CW. Haemodialysis-induced myocardial stunning in chronic kidney disease - a new aspect of cardiovascular disease. Blood Purif. 2010;29:105-110.
53. Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol. 2009;4:914-920.
54. Lameire N. Cardiovascular problems in ESRD patients. Nefrología 2000;20(suppl 3):33-40.
55. Stack AG, Molony DA, Rahman NS, Dosekun A, Murthy B. Impact of dialysis modality on survival of new ESRD patients with congestive heart failure in the United States. Kidney Int. 2003;64:1071-1079.
56. Konings CJ, Kooman JP, et al. Fluid status, blood pressure, and cardiovascular abnormalities in patients on peritoneal dialysis. Perit Dial Int. 2002;22:477-487.
57. Fagugli R, Reboldi G, et al. Short daily hemodialysis: blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients. Am J Kidney Dis. 2001;38:371-376.
58. Ayus JC, Achinger SG, Thadhani R. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol. 2005;16:2778-2788.
59. Pauly RP, Chan CT. Reversing the risk factor paradox: is daily nocturnal hemodialysis the solution? Semin Dial. 2007;20:539-543.
60. Chan CT, Floras JS, et al. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int. 2002;61:2235-2239.
61. Chan C, et al. Improvement in ejection fraction by nocturnal haemodialysis in end-stage renal failure patients with coexisting heart failure. Nephrol Dial Transplant. 2002;17:1518-1521.
62. Culleton BF, et al. Effect of frequent nocturnal hemodialysis versus conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA. 2007;298:1291-1299.
63. Chan CT, et al. Short-term blood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis. Hypertension. 2003;42:925-931.
64. Jefferies HJ, Virk B, Schiller B, et al. Frequent hemodialysis schedules are associated with reduced levels of dialysis-induced cardiac injury (myocardial stunning). Clin J Am Soc Nephrol. 2011;6:1326-1332.
65. Chertow GM, Levin NW, Beck GJ, et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med. 2010;363:2287-2300.
66. Kahn MR, Fallahi A, Kim MC, et al. Coronary artery disease in a large renal transplant population: implications for management. Am J Transplant. 2011;11:2665-2674.
67. Dzemidzić J, Rasić S, Saracević A, et al. Predictors of left ventricular remodeling in kidney transplant recipients in the first posttransplant year. Bosn J Basic Med Sci. 2010;10(suppl 1):S51-S55.
68. Wali RK, Wang GS, Gottlieb SS, et al. Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J Am Coll Cardiol. 2005;45:1051-1060.
69. Wong AK, Struthers AD, Choy AM, Lang CC. Insulin sensitization therapy and the heart: focus on metformin and thiazolidinediones. Heart Fail Clin. 2012;8:539-550.
70. Filion KB, Joseph L, Boivin JF, et al. Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus. Pharmacoepidemiol Drug Saf. 2011;20:785-796.